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Abstract
The American College of Card_iology and American Heart
Association published new blood cholesterol guidelines in
November 2013. The new guidelines place an emphasis on
evidence-based treatment of dyslipidemias and primarily use
randomized controlled trials to create recommendations for
health care providers. Major changes from the previous
guidelines include eliminating low-density lipoprotein goals,
the classification of statins by lipid-lowering potential and
the creation of four major statin benefit groups. The new
guidelines also establish the role of non-statins in dyslipidemias and use the Pooled Cohort Risk Assessment Equations
to calculate patients' risk for cardiovascular events and the
need for cholesterol-lowering medications. Pharmacists play
a vital role on the health care team and should be aware of
the changes in the cholesterol guidelines in order to improve
patient care.
Introduction
According to the Centers for Disease Control and Prevention
(CDC), 33.5 percent of American adults have elevated levels
of low-density lipoprotein cholesterol (LDL-C), causing hyperlipidemia.1 This is problematic because high LDL-C levels
are linked with an increased incidence of coronary heart disease (CHO), heart attack and stroke.2 Cardiac death remains
the number one cause of mortality in the United States.3
Many factors influence cholesterol levels, including diet,
weight, physical activity, gender, heredity variables and age.4
Because so many variables exist, treating hyperlipidemia can
be a complex process. Treatment complexity creates a need
for guidelines to help health care professionals manage their
patients' hyperlipidemia. The purpose of the following review is to inform pharmacists about the major changes between the Adult Treatment Panel (ATP) III hyperlipidemia
guidelines and the American College of Cardiology (ACC) and
the American Heart Association (AHA) guidelines that were
published in 2013.
Background-Development of New Cholesterol Guidelines
Before the new guidelines were established, the ATP III
guidelines released in 2001, and subsequently revised in
2004, were utilized by many health care professionals. These
guidelines had nine steps and set LDL-C goals, which were
the primary targets of therapy. They also suggested target
levels of total cholesterol and high-density lipoprotein (HDLC). Through the nine-step process, the evaluation of a patient
was completed and therapy was determined; treatment options included HMG-CoA reductase inhibitors, bile acid sequestrants, nicotinic acid and fibric acids. Additional risk (via
predisposed factors and a calculated Framingham Score)
could be calculated, and specific treatment guidelines were
outlined if the patient was presenting with metabolic synJuly 2014 Volume 5, Issue 3

drome or excessively high levels of triglycerides (TGs) . Overall, these previous guidelines were widely accepted by the
health care community.s
The new guidelines were written by the ACC and the AHA to
achieve the goals of decreasing the incidence of cardiovascular diseases and the management of existing disease states
through education, research, guidelines and standard practice. Four guidelines were created for: cardiovascular risk,
lifestyle modifications, management of blood cholesterol, and
management of obese and overweight adults. The ACC and
AHA collaborated with the National Heart, Lung and Blood
Institute (NHLBI) to develop these guidelines in the hopes
that they would improve upon the previous ATP III guidelines. The process for writing the new guidelines began in
2008 where the NHLBI wished to develop critical questions
(CQs) that would define the new guidelines through systematic evidence reviews. In 2011, the decision was made to select only the highest quality evidence to review, in response
to the Institute of Medicine's report of trustworthy clinical
guidelines. In June 2013, NHLBI began work with the ACC
and AHA to complete the four guidelines mentioned above,
making them pertinent to the widest population possible for
review. Expert panels did not evaluate evidence beyond
2011 (unless specified) and these guidelines are to be updated in 2014.6
Rigorous evidence review was performed in the creation of
these new guidelines. The ACC/AHA recruited unspecified
expert reviewers to examine the content of each document to
be used for the new guidelines and to certify that each one
had been peer reviewed by NHLBI Advisory Council representatives, key federal agencies and scientific experts; there
were no substantive changes made in content used as most
was undisputed. Evidence found through these randomized
controlled trials (RCTs), meta-analyses and observational
studies provided the ACC/AHA with information to classify
recommendations of treatment and procedures through the
grading of the strength of those recommendations with
grades A through E and grade N, which they established
themselves. Grade A indicates a strong recommendation,
meaning there is a high certainty that the net benefit is substantial with respect to evidence found. Grade D indicates a
recommendation against treatment due to evidence of risk or
harm to the patient Grades B and C fall between these two.
Grade E shows that evidence is insufficient but a recommendation was still made, and grade N shows that evidence suggests no recommendation for or against. If evidence was ambiguous or minimal, recommendations were not made using
those sources. These grades are used to notify the primary
care physicians or other medical professionals of the best
course of action to take based on evidence.6
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Three CQs embodied the guidelines: 1) What is the evidence
for LDL-C and non-HDL-C goals for the secondary prevention
of atherosclerotic cardiovascular disease (ASCVD)? 2) What
is the evidence for LDL-C and non HOL-C goals for the
primary prevention of ASCVD? and 3) For primary and secondary prevention, what is the impact on lipid levels, effectiveness, and safety of specific cholesterol-modifying drugs used
for lipid management in general and in selected subgroups?

Key Differences
No LDL Treatment Goals
The ATP III guidelines recommended LOL-C treatment goals
for patients depending on their risk of coronary heart disease. Those with CHO, a CHO risk equivalent (carotid artery
disease, peripheral artery disease, abdominal aortic aneurysm or diabetes), or a 10-year Framingham risk over
20 percent had an LOL-C goal of less than 100 mg/dL. Patients with moderate risk of cardiovascular events had an
LOL-C goal of less than 130 mg/dL, and those with a lower
risk had an LDL-C goal of less than 160 mg/dL. Risk factors
included age (men 45 years or older and women 55 years or
older), family history of premature CHO, cigarette smoking,
low HDL-C (less than 40 mg/dL) and hypertension (above
140/90 mmHg or on medications for blood pressure).5 The
2004 update to ATP III added an optional LDL-C goal of less
than 70 mg/dL in high-risk patients; this included patients
who have CHO with diabetes, metabolic syndrome, acute
coronary syndrome or severe uncontrolled risk factors. 7
Therapeutic lifestyle changes as well as cholesterol-lowering
medications could be used to reach an LDL-C goaJ.5

The Expert Panel that established the new ACC/AHA guidelines eliminated LDL-C and non-HDL treatment goals for patients. Instead, the panel created four major statin benefit
groups with a specific statin intensity level that provides optimal treatment of patients within each group. Treatment
goals were not included because the Panel did not find evidence in RCTs to support utilizing specific LDL-C and nonHDL goals. All RCTs reviewed by the Panel compared statins
to a placebo or compared lower dose statins to higher dose
statins; no RCTs that involved titrating statin doses to reach
specific LDL-C or non-HOL goals were found, and there was
thus no evidence to recommend specific treatment goals for
patients like those included in ATP III. The RCT evidence instead showed that it is necessary to use the appropriate
statin intensity in the major statin benefit groups in order to
reduce the risk of ASCVD.6
Additionally, the Expert Panel found that treating LDL-C to a
certain goal allowed undertreatment or overtreatment of
many patients at risk for ASCVD. For instance, a patient who
has not reached the LDL-C goal assigned by his doctor may
have been prescribed a non-statin to help further lower cholesterol; this new medication puts the patient at risk for
more side effects and drug interactions. This would now be
considered overtreatment if the patient is already taking the
recommended intensity of statin for his ASCVD risk factors;
non-statins will be discussed later in this article, but overall
the new guidelines do not support the use of non-statins in
cholesterol-lowering alone or in combination with statins.
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Undertreatment can occur when a patient reaches their LDLC goal while taking a suboptimal statin dose for his risk of
ASCVD, and therefore his or her dose is never increased to an
appropriate level as defined by the new guidelines.6
To monitor a patient's adherence to statin therapy, a baseline
lipid panel should be taken as well as a second lipid panel
four to 12 weeks after statin therapy is started; after this initial assessment, lipid panels should be completed every three
to 12 months as necessary. Baseline liver function tests
should be obtained, but it is not necessary to continue measuring liver function unless the patient has symptoms of hepatotoxicity. In patients with an increased risk of muscle pain
(such as those with a personal or family history of muscle
pain, statin intolerance or the presence of a concomitant
medication that increases the risk of myopathy), it is reasonable to get a baseline creatine kinase and then remeasure
creatine kinase if muscle symptoms develop.6
Statin Classification Groups
The Panel defines the intensity of statin therapy based on the
expected percent LDL-C response to a certain statin and its
dose. The definitions "high-intensity," "moderate-intensity"
and "low-intensity" statin therapy were developed from the
Panel's systematic reviews of RCTs and meta-analyses. Highintensity statin therapy lowers LDL-C by ;e:SO percent, moderate-intensity statin therapy lowers LDL-C by 30 percent to
<SO percent, and low-intensity statin therapy lowers LOL-C
by <30 percent. Evidence showed the relative decrease in
ASCVD risk from statin medications is related to the degree
by which LDL-C is lowered, rather than having a specific
treatment goal.& See Table 1 for a summary of lipid lowering
potential of the various statins.
Four Major Statin Benefit Groups
Whereas ATP lII classified patients into risk groups in order
to develop LDL-C treatment goals, the new guidelines created
four major statin benefit groups in which the benefits of reducing the risk of ASCVO outweigh potential adverse effects
of statins. These groups were established from RCT data that
showed primary and secondary prevention of ASCVO with
moderate-intensity and high-intensity statins; evidence of
ASCVO outcomes was used to determine "who should get
which therapy at what intensity."6

The first benefit group consists of individuals with clinical
ASCVD, which is defined as a history of myocardial infarction,
acute coronary syndromes, coronary or arterial revascularization, stable or unstable angina, peripheral arterial disease
of an atherosclerotic origin, or stroke or transient ischemic
attack Because these patients have a high risk of ASCVD
events and subsequent death, high-intensity statins are recommended if they are 75 years old or younger. Moderateintensity statins should be used in patients over 75 years of
age because there is no data to show additional ASCVD risk
reduction with high-intensity statins in this population, but
there is an increased risk of adverse events. &
Patients with an LOL-C of 190 mg/dL or higher constitute the
second major statin benefit group. Elevations of LDL-C of
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Table 1. High-Intensity, Moderate-Intensity and Low-Intensity Stalin Therapy6
High-Intensity Stalin Therapy

Moderate-Intensity Statin Therapy

Low-Intensity Stalin Therapy

Daily dose lowers LDL-C on
average, by approximately ~50%

Daily dose lowers LDL-C on
average, by approximately 30% to
<50%

Daily dose lowers LDL-C on
average, by approximately 30% to
<50%

Atorvastatin 40t-BO mg
Rosuvastatin 20 (40) mg

Atorvastatin 10 (20) mg
Rosuvastatin (5) 10 mg
Simvastatin 20-40 mg:j:
Pravastatin 40 (80)
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40mg bid
Pitavastatin 2-4 mg

Simvastatin 10 mg
Pravastatin 10-20 mg
Lovastatin 2 0 mg
Fluvastatin 20-40 mg
Pitavastatin 1 mg

Specific statins and doses in bold were evaluated in RCTs or meta-analysis and demonstrated a reduction in major
cardiovascular events. Sta tins and doses that are italicized are approved by the FDA but were not tested in the RCTs.
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice.
There may be a biologic basis for a less-than-average response.
tEvidence from 1 RCT only
:j:Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg
is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis.
190 mg/ dL or higher lead to a higher lifetime risk of ASCVD
and are often associated with a genetic predisposition for
hypercholesterolemia. High-intensity statins are recommended for these patients to reduce ASCVD risk; non-statins
can also be used in these patients to further lower LDL-C if it
has not reached the expected level of lowering or the level is
still undesirable for the patient's risk of ASCVD.6

For all benefit groups, patients who cannot tolerate the recommended statin intensity should be prescribed the highest
intensity statin that they are able to tolerate.6

Individuals with diabetes between the ages of 40 and 75
years make up the third statin benefit group. Diabetes causes
an increased lifetime ASCVD risk and leads to greater morbidity and mortality once ASCVD develops. Diabetics with an
estimated 10-year ASCVD risk calculated with the Pooled
Cohort Risk Assessment Equations (which will be described
later in this article) of 7.5 percent or greater should receive
high-intensity statin therapy; moderate-intensity statins are
recommended for diabetics with a lower estimated 10-year
ASCVD risk. Clinical judgment should be exercised when
evaluating diabetics who are less than 40 years old or over
75 years old.6

Role of Non-Statins
Another significant change related to cholesterol therapy
recommendations involves non-statin medications; however,
first-line recommendations are similar to previous
guidelines. Like the ATP III guidelines, the new guidelines
recommend statins as the drugs of first choice for treating
hyperlipidemia. 6 Research has consistently shown that
statins are the most effective drugs for lowering LDL-C.
Additionally, statins are generally safe and well-tolerated
medications.s,6 The Panel concluded that statin therapy is far
superior to any other medication on the market. The clinical
trials reviewed on non-statin medications lacked clinical efficacy or were unreliable. With numerous trials supporting
statin use and limited evidence favoring non-statin medications, the Panel restricts its recommendations on non-statin
medications to a few circumstances.6

Finally, the last major statin benefit group is comprised of
patients between 40 and 75 years old with an LDL-C between
70 and 189 mg/ dL who do not have clinical ASCVD or diabetes. The risk of ASCVD in these patients who have a 7.5 percent or higher estimated 10-year ASCVD risk is reduced with
either moderate-intensity or high-intensity statin therapy.
Clinical judgment and patient preference should be included
in the decision as to what intensity is appropriate for the patient and for patients with a lower estimated 10-year ASCVD
risk.6

Non-statin therapies discussed in the old guidelines included
bile acid sequestrants, nicotinic acid, fibric acid derivatives
(fibrates), hormone replacement therapy (HRT) and selective estrogen receptor modulators (SERMs). Though statins
were still recommended as first-line treatment, these nonstatin therapies were recommended liberally. For instance,
bile acid sequestrants could be used in patients with moderate elevations in LDL-C, in younger patients with high LDL-C
levels, in women with high LDL-C considering pregnancy, in
patients only needing modest decreases in LDL-C and for
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combination therapy in patients with highly elevated LDL-c.s
Under the new guidelines, non-statin therapy is only recommended if the following criteria are met: the patient has a
high ASCVD risk and is currently on the maximum tolerated
intensity of statin therapy and continues to have a response
less than expected and if the ASCVD risk-reduction benefits
outweigh the potential for adverse effects or if a patient is a
candidate for statin treatment but is completely statin intolerant. Statin intolerant patients are those who experience
serious side effects such as myalgia, rhabdomyolysis and elevated hepatic aminotransferases during statin use. High-risk
individuals include those with clinical ASCVD <75 years of
age, individuals with baseline LDL ~190 mg/dL, and individuals 40 to 75 years of age with diabetes.6 See Figure 1 for
a summary of the recommendations.
The Panel suggests that health care providers review patients' adherence to both lifestyle changes and medications
and rule out secondary causes of hyperlipidemia before considering non-statins. Research showed non-statins do not
provide acceptable ASCVD risk reduction benefits compared
to their potential for adverse effects. In the few studies on
non-statin medications that have been conducted, nonstatins did not show significant additional ASCVD event reductions as compared to statins.6.B
As an example, in the Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglyceride and
Impact on Global Health Outcomes (AIM-HIGH) trial, researchers looked at whether or not increasing HDL-C with
extended-release niacin along with decreasing LDL-C with
simvastatin would decrease the number of cardiovascular
disease events. All patients were given 40 mg of simvastatin
and then randomized to receive either niacin or placebo.
Patients taking simvastatin with niacin saw increased
reductions in LDL-C and TGs with increases in HDL-C. However, there was no difference in the number of CVD events as
compared to placebo. The trial was discontinued early due to
a lack in incremental benefit in CVD events and an unexplained increase in ischemic stroke in the niacin treatment
group.6,9,10
Similarly, in the Action to Control Cardiovascular risks in
Diabetes (ACCORD) trial, researchers sought to determine
whether or not fenofibrate treatment reduces the risk of CVD
events. Patients were randomized into two groups: simvastatin with fenofibrate or simvastatin plus placebo. Again, the
addition of a non-statin did not significantly reduce the risk
of CVD events. Unlike niacin combination therapy, fenofibrate combination therapy did not additionally lower LDL-C
levels and only had a minimal to moderate impact on HDL-C
and TGs respectively. In a small patient group on fenofibrate
and simvastatin, patients might have had a decrease in CVD
events. Participants affected included those with TGs ~204
mg/dL and HDL-C ~40 mg/dL. Side effects in both treatment
groups were similar except in regard to increased creatinine
levels and elevated alanine aminotransferase levels. Patients
on fenofibrate and simvastatin had an increased incidence of
an alanine aminotransferase (ALT) greater than five times
the upper limit of normal. The number of CVD events in
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women with controlled diabetes was higher in the fenofibrate and simvastatin group as compared to placebo. The
lack of a significant decrease in CVD events and the seemingly increased risk of certain adverse events with fenofibrate use with simvastatin led the Panel to forgo
recommending fenofibrate as first-line therapy for hyperlipidemia.6·11
The Panel also questioned the validity and generalizability of
the other non-statin studies reviewed.a These new non-statin
recommendations may decrease the sales of non-statins and
simplify patients' treatment regimens, since they highly encourage physicians to prescribe statins.
Pooled Cohort Risk Assessment Equations
The Pooled Cohort Risk Assessment Equations were developed by the Risk Assessment Work Group in order to estimate the 10-year ASCVD risk, which is utilized to identify
individuals who are candidates for statin therapy. These
equations can be used to predict stroke in patients and to
also predict CVD related events in patients who are nonHispanic Caucasians and African-Americans. Patients who
can be evaluated with these equations may be between ages
40 and 79, may be with or without diabetes, and have LDL-C
levels of 70 to 189 mg/dL. The risk assessment does not require the counting of risk factors for determining statin therapy initiation. Rather, it focuses on evidence from a global
ASCVD risk assessment. This assessment is derived from trials in which statin effectiveness in various patient subgroups
was determined (where statins reduce ASCVD events despite
existing risk factors). Statin efficacy for improvement of
ASCVD events versus statin adverse effects was used for
identifying groups of patients who could benefit from the use
of statins. Currently, there is an underestimation of high-risk
patients who would benefit from statin therapy given the
evidence found through reviewing RCT data, but the new
guidelines also overestimate the portion of the population
who are considered low-risk patients who may benefit from
statin therapy. These 10-year ASCVD risk assessments create
a large gray area in the medical field in regard to where the
use of statins may now be warranted, because some patients
who would not have qualified to receive a statin according to
the previous ATP III guidelines, would now qualify based on
the new guidelines.6,12

Limitations to the New Guidelines
There are several limitations to these new cholesterol guidelines. First, the guidelines focus on patient populations that
are represented well in RCTs; there are some patients with a
high risk of ASCVD who were not represented well in RCTs
and were thus excluded from the guidelines. Clinical judgment is important in patient care, particularly where RCT
data is lacking as well as in patient populations excluded
from the guidelines; the guidelines should not replace clinical
judgment, but should be used to inform health care providers. Another limitation is that an independent contractor
graded the quality of the evidence used to develop the guidelines. The Expert Panel only considered RCTs, systematic
reviews, and meta-analyses graded as fair to good quality by
the independent contractor and therefore could have missed
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Figure 1. Statin Therapy Monitoring Therapeutic Response and Adherence.
r

Statin Therapy: Monitoring therapeutic response and adherence
{See 2013 ACC/AHA Blood Cholesterol Guideline)

Assess medication and lifestyle adherence

Fasting lipid panel*

-

-

-

Indicators of anticipated therapeutic response and
adherence to selected statin therapy:
• High-intensity statin therapyt reduces LDL-C
approx. ~50% from the untreated baseline.
• Moderate-intensity statin therapy reduces LDL-C
approx. 30% to <50% from the untreated
baseline .

. - - - -Yes ....------~-No--------------

Reinforce continued adherence
Follow-up 3-12 mo

Less-than-anticipated
therapeutic response

Yes

Management of
statin intolerancet

Reinforce improved adherence
Increase statin intensity
OR
Consider addition of nonstatin drug therapy

Follow-up 4-12 wk &
thereafter as indicated

No

Reinforce medication
adherence
Reinforce adherence to intensive
lifestyle changes
Exclude secondary causes of
hypercholesterolemia

Follow-up 4-12 wk

In: ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report
of the American College of Cardiology/American Heart Association task force on practice guidelines. 2013. Available from:
http://circ.ahajournals.org/content/suppl/2013/11/07 /01.cir.0000437738.63853.7a.DC1. Accessed April 15, 2014.
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potentially relevant data in observational studies not included in the analysis.6
Further research is necessary in order to update the guidelines in the future, particularly in areas where evidence is
currently lacking. The RCTs in the future could study the effects of titrating a statin dose to achieve a specific LDL-C goal
compared to a single fixed dose. Other subgroups that could
benefit from statin therapy may also be found through RCTs
and observational studies as well as additional information
on the current benefit groups. Studies can also be conducted
to learn more about adding non-statin therapies to achieve
cholesterol-lowering and potential LDL-C treatment goals.6,l3
These new ACC/AHA cholesterol guidelines have been very
controversial among health care professionals. First, many
providers disagree with the lack of LDL-C or other treatment
goals for patients; the lack of goals makes long-term followup and monitoring seem unnecessary if there is no way to
monitor the patient's progress. Additionally, patient's LDL-C
values helped to monitor the residual risk of ASCVD events
while on statin therapy, and the new guidelines do not account for the pathophysiology of cardiovascular disease.
Next, the new guidelines state that non-statins do not add to
cholesterol lowering and reduction of ASCVD risk when combined with statins. This may deter pharmaceutical companies
from pursuing the production of non-statin medications and
prevent new cholesterol-lowering medications from being
developed. Because multidrug therapy is frowned upon in
these guidelines, patients who could benefit from multiple
cholesterol-lowering medications can be prevented from
receiving this treatment; this includes patients with cardiovascular disease who are on the maximum dose of a highintensity statin and still have high cholesterol.13-15
The new guidelines only cover patients who are between the
ages of 40 and 75, which leaves providers with no guidance
for patients who are younger or older than this; by the time a
patient without ASCVD who has an LDL-C of 180 mg/dL and
other risk factors for ASCVD is 40 years old, it is often too
late for effective prevention of ASCVD itself, but statins must
be used to reduce the risk of recurrent ASCVD events. Finally,
the guidelines did not include LDL-C treatment goals because
the Expert Panel believed that treatment goals lead to undertreatment or overtreatment of many patients in order to
reach the LDL-C goal. However, the new guidelines can still
lead to undertreatment and overtreatment. In the example
above, the patient with ASCVD risk factors is not receiving
statin therapy to prevent the development ASCVD because
the risk calculator is not designed to be used until age 40,
and even then the patient might not have a 7.5 percent or
higher estimated 10-year ASCVD risk; this would be considered undertreatment since he or she is not receiving appropriate care to prevent ASCVD.13-15

Role of Pharmacists
Pharmacists play an important role in cholesterol management and need to be aware of the changes made with the
ACC/ AHA guidelines. Pharmacists are able to educate patients on the proper use and adverse effects of the medica-
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tions they are prescribed; in addition, they can answer questions that patients have about their cholesterol and the new
guidelines. As the drug experts on the health care team, pharmacists can inform other providers on appropriate statins to
use in specific patient populations and about non-statin options in patients who need additional cholesterol lowering or
cannot tolerate statins as well as ensure that statins are a
necessary and safe addition to a patient's therapy.16,17

Conclusion
The new ACC/ AHA cholesterol guidelines are a major shift in
the treatment approach to dyslipidemias. Statins are considered the mainstay of cholesterol-lowering therapy and
should be the drug of choice in any patient requiring treatment for dyslipidemia or to prevent ASCVD. Non-statins play
a minor role in lipid-lowering therapy and are therefore not
recommended by the guidelines unless a patient is statin
intolerant. The guidelines created four major statin benefit
groups, and each group has a statin intensity appropriate to
treat patients falling within that category. Pharmacists are
well positioned to apply the new guidelines in cholesterol
management as well as educate patients about the new
guidelines and the role of statins in lowering cholesterol.
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